|
Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing scalable human cell models derived from induced pluripotent stem cells (iPSCs), announces the commercial release of TrailBio Hematopoietic Progenitor Cells. These progenitor cells are derived from a single, well-characterized iPSC line using Trailhead’s proprietary High-Dimensional Design-of-Experiments (HD-DoE) platform, providing researchers with a consistent, scalable, and ready-to-use tool for hematopoietic research.
TrailBio Hematopoietic Progenitor Cells express key hematopoietic markers including CD34, CD43 and CD90. Functional characterization confirms their ability to form myeloid and erythroid colonies in colony-forming unit (CFU) assays, differentiate into multiple hematopoietic lineages and demonstrate hematopoietic commitment through transcriptomic profiling.
Designed for applications such as hematopoietic disease modelling, drug screening and hematotoxicity studies, TrailBio Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results.
“TrailBio Hematopoietic Progenitor Cells strengthen our portfolio by providing researchers with high-quality, human-relevant cellular models,” said David Llewellyn, chief executive officer of Trailhead Biosystems. “Their consistency and multipotency enable scientists to advance research in hematopoietic biology and therapeutic development.”
“These Hematopoietic Progenitor Cells deliver a dependable combination of purity, potency and versatility,” said Angelica Gomes Ueltschy, scientific director at Trailhead Biosystems. “Their robust marker expression and multilineage differentiation capacity make them well suited for modelling blood disorders and evaluating therapeutic candidates.”
Trailhead Biosystems, Inc. is pioneering an informatics-based approach in regenerative medicine and drug discovery. Founded in 2015 as a spinout from the Cleveland Clinic and Case Western Reserve University, Trailhead emerged from the research of CSO/CTO and founder Dr. Jan Jensen.
|